Where does Direct-to-Patient fit in a post-Covid world?

17th May 2022

The impact of the COVID-19 pandemic has propelled a historic and transformational shift in the clinical research industry, transforming clinical trials. This has meant finding alternative ways of working, such as utilizing new routes and adjusting study protocols, including a rise in demand for direct-to-patient delivery.

In this on-demand webinar we take a look at the premise of this model, how investigational medicinal products (IMP) or drugs are administered in the patient’s home, and the challenges and risks involved.

Watch our expert CEO Dr Graham Wylie discuss with World Courier’s experts below.

Back to the resources